That’s a good point. So maybe another point of divergence here is that the outcomes of the DMA are rooted in inherently unpredictable market interactions, whereas a medical device standard depends on the device performance and characteristics.

I don’t think it makes sense to create an accountability framework for a company that requires the cooperation of the market, because I think companies should be in a position to either comply or be held accountable on their own merits